Cytokeratin 5 (CK5) is a type II cytokeratin. CK5 labels myoepithelial cells of breast and prostate basal cells. The human type II Cytokeratin 6 (CK6) is expressed on stratified epithelia including oral mucosa, esophagus, basal layer of epidermis, the outer root sheath of hair follicles, and in glandular epithelia. CK6 is a marker of hyperproliferative and activated keratinocytes found in psoriasis. Eighty percent of prostate tumors contain genomic fusions of TMPRSS2 and members of the ETS family of transcription factors. Of these, about 50% contain TMPRSS2-ERG fusions. CK5 & CK6 & ERG cocktail might be used for differentiate benign abd malignant prostate tumor. The ERG antibody labels prostate cancer cells, endothelial cells, and lymphocytes.
Cytokeratin 5 (CK5) is a type II cytokeratin. CK5 labels myoepithelial cells of breast and prostate basal cells. The human type II Cytokeratin 6 (CK6) is expressed on stratified epithelia including oral mucosa, esophagus, basal layer of epidermis, the outer root sheath of hair follicles, and in glandular epithelia. CK6 is a marker of hyperproliferative and activated keratinocytes found in psoriasis. Eighty percent of prostate tumors contain genomic fusions of TMPRSS2 and members of the ETS family of transcription factors. Of these, about 50% contain TMPRSS2-ERG fusions. CK5 & CK6 & ERG cocktail might be used for differentiate benign abd malignant prostate tumor. The ERG antibody labels prostate cancer cells, endothelial cells, and lymphocytes.
Cytokeratin 5 (CK5) is a type II cytokeratin. CK5 labels myoepithelial cells of breast and prostate basal cells. The human type II Cytokeratin 6 (CK6) is expressed on stratified epithelia including oral mucosa, esophagus, basal layer of epidermis, the outer root sheath of hair follicles, and in glandular epithelia. CK6 is a marker of hyperproliferative and activated keratinocytes found in psoriasis. Eighty percent of prostate tumors contain genomic fusions of TMPRSS2 and members of the ETS family of transcription factors. Of these, about 50% contain TMPRSS2-ERG fusions. CK5 & CK6 & ERG cocktail might be used for differentiate benign abd malignant prostate tumor. The ERG antibody labels prostate cancer cells, endothelial cells, and lymphocytes.
